BioStock: Green light to continue Elicera’s CARMA-trial in B-cell lymphoma

Elicera Therapeutics has received the green light from the Data Safety and Monitoring Board (DSMB) to continue its phase I/IIa clinical trial, CARMA, evaluating the CAR T-cell therapy candidate ELC-301 for B-cell lymphoma. Armed with immune-activating properties via the company’s iTANK platform, the therapy is a key component of Elicera’s broader immunotherapy strategy. The approval comes as the company prepares to present preliminary efficacy data from the first patient cohort in May.

Read the article at biostock.se:

https://www.biostock.se/en/2025/04/green-light-to-continue-eliceras-carma-trial-in-b-cell-lymphoma/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/